This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IART Stock May Rise on First Enrollment in AERA Pediatric Registry
by Zacks Equity Research
Integra enrolls first pediatric patient in AERA registry to evaluate real-world use of its ETBD system and expand ENT market presence.
Teleflex Acquires BIOTRONIK's Vascular Intervention Business, Stock Up
by Zacks Equity Research
TFX gains 2.9% after acquiring BIOTRONIK's vascular unit, boosting its cath lab presence and innovation pipeline.
Here's Why You Should Add HealthEquity Stock to Your Portfolio Now
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
Abbott Sees Upside on Diagnostics Growth, FreeStyle Libre Expansion
by Zacks Equity Research
ABT stock surges 21.7% year to date on CGM sales growth and robust diagnostics demand, even as FX and macro risks weigh on forecasts.
Is Quest Diagnostics Stock a Smart Pick for Your Portfolio Now?
by Zacks Equity Research
DGX rides on double-digit diagnostics growth and a wave of strategic acquisitions despite rising debt and policy headwinds.
COO Stock Declines Despite Strong Core Growth Amid Fertility Woes
by Zacks Equity Research
The Cooper Companies grows margins and premium products, but fertility softness, inventory cuts, and tariffs weigh on the near-term outlook.
Is it Apt to Retain Alcon Stock in Your Portfolio for Now?
by Zacks Equity Research
ALC stays on investors' radar due to its Vision Care arm's performance and contributions from new products despite macro risks and stiff competition.
Boston Scientific Climbs 40.5% in a Year: What's Driving the Stock?
by Zacks Equity Research
BSX rallies 40.5% in a year, fueled by WATCHMAN growth, MedSurg gains, acquisitions and global expansion efforts.
Phibro Animal Health Stock Up 52.8% in a Year: What's Driving the Rise?
by Zacks Equity Research
PAHC stock is under investors' radar due to its booming animal health sales, new product lines and rising vaccine demand.
BRKR Stock Gains Following the Multi-System Advanced Packaging Order
by Zacks Equity Research
Bruker ships and installs its 15th InSight WLI system as part of a 27-optical metrology unit order tied to AI chip packaging demand.
SYK Boosts Foot & Ankle Portfolio With FDA-Cleared Total Ankle System
by Zacks Equity Research
Stryker expands its Foot & Ankle portfolio with FDA-cleared InCompass, targeting streamlined total ankle replacement.
Reasons to Add Align Technology Stock to Your Portfolio Now
by Zacks Equity Research
ALGN's Invisalign growth, iTero innovation and solid finances fuel optimism despite forex headwinds.
GEHC Stock Gains Post FDA's Nod for Vizamyl's Expanded Indications
by Zacks Equity Research
GE HealthCare gains FDA nod to expand Vizamyl's use, unlocking new diagnostic and therapy-monitoring capabilities.
Should You Continue to Retain Abbott Stock in Your Portfolio Now?
by Zacks Equity Research
ABT rides on strong global demand in diagnostics and diabetes care, but macro headwinds may test its momentum ahead.
Is This the Right Time to Hold EYE Stock in Your Portfolio?
by Zacks Equity Research
National Vision gains from America's Best momentum and strategic revamp, but solvency issues and rising costs weigh on profitability.
TNDM Stock Gains on t:slim X2's Compatibility With FreeStyle Libre 3 +
by Zacks Equity Research
Tandem Diabetes' t:slim X2 pump with Control-IQ+ tech gains U.S. early access using FreeStyle Libre 3 Plus sensor.
QIAGEN's New QIAcuity dPCR IVD Pact With GENCURIX May Boost Its Stock
by Zacks Equity Research
QGEN teams with GENCURIX to expand its digital PCR IVD offerings, aiming to strengthen its precision diagnostics arm.
ABT's i-STAT TBI Test Receives Approval in Canada: Stock to Rise?
by Zacks Equity Research
Abbott gains Health Canada approval for its i-STAT TBI test, enabling rapid bedside concussion detection via whole blood.
Should You Add NVST Stock to Your Portfolio Right Now?
by Zacks Equity Research
Envista's global expansion, smart acquisitions, and strong balance sheet support growth but forex risks remain a drag.
Reasons to Add PAHC Stock to Your Portfolio Right Now
by Zacks Equity Research
Phibro's strong Animal Health momentum and global expansion bode well for investors.
Labcorp Stock Climbs 25.6% This Year: What's Driving the Surge?
by Zacks Equity Research
LH stock surges 25.6% this year, powered by specialty testing expansion, key acquisitions and solid financials.
DGX Stock Up on New Blood Test Development Deal With MD Anderson
by Zacks Equity Research
DGX stock rises on a new partnership with MD Anderson to develop a blood test targeting multiple cancer risks.
GEHC Stock Declines Despite Expansion in Precision Care Capabilities
by Zacks Equity Research
GE HealthCare integrates proprietary algorithms into MIM Encore to advance digital imaging and workflow precision.
Take the Zacks Approach to Beat the Markets: Mirion Technologies, Avino Silver & Gold Mines, Quanta Services in Focus
by Santanu Roy
MIR, ASM and PWR outperform the S&P 500 after Zacks upgrades, spotlighting key stock picks in a volatile market.
QGEN Stock Rises in After Market Following Partnership With Incyte
by Zacks Equity Research
QIAGEN teams up with Incyte to develop NGS-based companion diagnostics for blood cancers.